[A25-54] Trastuzumab deruxtecan (breast cancer) – Benefit assessment according to §35a Social Code Book V
Last updated 01.08.2025
Project no.:
A25-54
Commission:
Commission awarded on 28.04.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A25-54
| Project no. | Title | Status |
|---|---|---|
| A22-80 | Trastuzumab deruxtecan (breast cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A22-81 | Trastuzumab deruxtecan (breast cancer, HER2+, at least 2 prior therapies) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-07 | Trastuzumab deruxtecan (breast cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-08 | Trastuzumab deruxtecan (gastric cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-115 | Trastuzumab deruxtecan (NSCLC) – Benefit assessment according to §35a Social Code Book V | Commission completed |